- Home
- HCVI vs CMPX Comparison
HCVI vs CMPX Comparison
Compare HCVI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCVI
- CMPX
- Stock Information
- Founded
- HCVI 2021
- CMPX 2014
- Country
- HCVI United States
- CMPX United States
- Employees
- HCVI N/A
- CMPX N/A
- Industry
- HCVI Blank Checks
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- HCVI Finance
- CMPX Health Care
- Exchange
- HCVI Nasdaq
- CMPX Nasdaq
- Market Cap
- HCVI 176.6M
- CMPX 217.4M
- IPO Year
- HCVI 2021
- CMPX N/A
- Fundamental
- Price
- HCVI $10.66
- CMPX $1.54
- Analyst Decision
- HCVI
- CMPX Strong Buy
- Analyst Count
- HCVI 0
- CMPX 2
- Target Price
- HCVI N/A
- CMPX $9.00
- AVG Volume (30 Days)
- HCVI 33.9K
- CMPX 370.5K
- Earning Date
- HCVI 01-01-0001
- CMPX 11-07-2024
- Dividend Yield
- HCVI N/A
- CMPX N/A
- EPS Growth
- HCVI N/A
- CMPX N/A
- EPS
- HCVI N/A
- CMPX N/A
- Revenue
- HCVI N/A
- CMPX $850,000.00
- Revenue This Year
- HCVI N/A
- CMPX N/A
- Revenue Next Year
- HCVI N/A
- CMPX $950.68
- P/E Ratio
- HCVI N/A
- CMPX N/A
- Revenue Growth
- HCVI N/A
- CMPX N/A
- 52 Week Low
- HCVI $10.30
- CMPX $0.77
- 52 Week High
- HCVI $11.47
- CMPX $2.34
- Technical
- Relative Strength Index (RSI)
- HCVI 60.14
- CMPX 64.03
- Support Level
- HCVI $10.62
- CMPX $1.42
- Resistance Level
- HCVI $10.66
- CMPX $1.65
- Average True Range (ATR)
- HCVI 0.01
- CMPX 0.13
- MACD
- HCVI 0.00
- CMPX 0.01
- Stochastic Oscillator
- HCVI 100.00
- CMPX 66.01
About HCVI Hennessy Capital Investment Corp. VI
Hennessy Capital Investment Corp VI is a shell company.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.